On September 10, 2019 Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, reported an oral presentation at the upcoming European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2019 being held in Barcelona, Spain from September 27 – October 1, 2019.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will focus on the nature of the patient population and the activity of CLR 131 in these heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).

Presentation details

Title: Interim Evaluation of a Targeted Radiotherapeutic, CLR 131, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients (R/R DLBCL)
Presenter: Jarrod Longcor
Session: Proffered Paper Session – Presentation #1065O
Date/Time: September 28, 2019 / 2:45 pm – 3:00 pm CET
Location: Toledo Auditorium (Hall 5), Fira Gran Via, Barcelona, Spain

A copy of the presentation materials can be accessed on the Posters and Publications section of the Cellectar website once the presentation concludes.